Company:  GENOCEA BIOSCIENCES, INC. (GNCA)
Form Type:  S-1MEF
Filing Date:  6/19/2019 
CIK:  0001457612 
Address:  100 ACORN PARK DRIVE 
City, State, Zip:  CAMBRIDGE, Massachusetts 02140 
Telephone:  617-876-8191 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.68  
Change: 
0.07 (2.68%)  
Trade Time: 
Oct 15  
Market Cap: 
$70.08M
Trade GNCA now with

© 2019  
Description of Business
Unless the context requires otherwise, references in this Annual Report on Form 10-K to "Genocea", "we", "us" and "our" refer to Genocea Biosciences, Inc. Overview We are a biopharmaceutical company that seeks to discover and develop novel cancer immunotherapies. We use our proprietary discovery platform, ATLAS, to profile CD4+ and CD8+ T cell (or cellular) immune responses to tumor antigens. We use insights arising from ATLAS to design novel cancer immunotherapies. We believe that ATLAS, which recreates each individual's T cell immune responses to their tumor in the laboratory, affords Genocea advantages in the design of novel cancer immunotherapies relative to our peers, who we believe rely primarily on software and processes such as "machine learning" to predict immunotherapy targets. Our most advanced program is GEN-009, a neoantigen (or personalized) cancer vaccine, for which we are conducting a Phase 1/2a clinical trial.
Register and access this filing in:     
  FORM S-1MEF
    CALCULATION OF REGISTRATION FEE
    EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
    EXHIBIT LIST
    SIGNATURES
  EXHIBIT 5.1
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM